###begin article-title 0
Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses' Health Study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 208 214 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 344 350 344 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 354 360 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human fibroblast growth factor (FGF) and its receptor (FGFR) play an important role in tumorigenesis. Deregulation of the FGFR2 gene has been identified in a number of cancer sites. Overexpression of the FGFR4 protein has been linked to cutaneous melanoma progression. Previous studies reported associations between genetic variants in the FGFR2 and FGFR4 genes and development of various cancers.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 147 153 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
We evaluated the associations of four genetic variants in the FGFR2 gene highly related to breast cancer risk and the three common tag-SNPs in the FGFR4 gene with skin cancer risk in a nested case-control study of Caucasians within the Nurses' Health Study (NHS) among 218 melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases, and 870 controls.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
We found no evidence for associations between these seven genetic variants and the risks of melanoma and nonmelanocytic skin cancer.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 102 108 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 173 178 <span type="species:ncbi:9606">women</span>
Given the power of this study, we did not detect any contribution of genetic variants in the FGFR2 or FGFR4 genes to inherited predisposition to skin cancer among Caucasian women.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 181 182 181 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 554 555 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 775 777 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human fibroblast growth factor (FGF) and its receptor families consist of 22 structurally related FGF members and four high-affinity tyrosine kinase FGF receptors (FGFR1 to 4) [1,2]. The four FGFRs generate ligand-binding specific isoforms by tissue-specific alternative mRNA splicing of the genes [3-7]. FGFs and their receptors have an important role in cell signaling [8]. The formation of the FGF-FGFR complex activates the intracellular tyrosine kinase, which mediates signal transduction through the direct phosphorylation of adaptor proteins [9]. These complex FGF signaling networks are crucial in the multiple cell biological activities, such as proliferation, differentiation, mitogenesis, migration, and apoptosis, and are thus implicated in tumorigenesis [10-12].
###end p 11
###begin p 12
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2</italic>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 395 401 395 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 480 486 480 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 562 568 562 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 598 604 598 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 775 777 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 871 877 871 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 223 238 <span type="species:ncbi:10090">transgenic mice</span>
###xml 681 686 <span type="species:ncbi:9606">human</span>
The FGFR2, known as a unique high-affinity receptor for keratinocyte growth factor (KGF or FGF7), is expressed in the keratinocytes of the skin epidermis, hair follicles, and mesenchymal tissues [5,13,14]. An experiment in transgenic mice with FGFR2 mutation in the keratinocyte showed that normal signal transduction was blocked by binding of its ligand KGF [15]. It has been reported that the FGFR2 plays a role in tumor suppression in the skin [16]. In addition, the increased FGFR2 gene expression has been related to the genetic variants in intron 2 of the FGFR2 gene [17] and deregulation of FGFR2 gene expression and/or gene mutation has been identified in various kinds of human cancers, such as breast, prostate, endometrial, colon, bladder, and thyroid cancers [17-22]. Recently, two genome-wide association studies have identified some genetic variants in the FGFR2 gene that were highly associated with breast cancer [23,24].
###end p 12
###begin p 13
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 390 396 390 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
The FGFR4 gene located on the chromosome 5 spans approximately 11.3 kb and is composed of 18 exons [25]. Overexpression of the FGFR4 protein has been associated with cutaneous melanoma progression [26]. High expression of FGFR4 has also been observed in breast cancer, prostate cancer, pancreatic cancer, and renal cell carcinoma [27-30]. Furthermore, SNP rs351855 located in exon 9 of the FGFR4 gene results in an amino acid change (Gly388Arg) in the transmembrane domain of the receptor and has been associated with tumor progression in, for example, cutaneous nodular malignant melanoma, breast cancer, lung adenocarcinoma, prostate cancer, and head and neck cancer [26,31-36].
###end p 13
###begin p 14
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
We conducted a nested case-control study of Caucasians within the Nurses' Health Study (NHS) to evaluate whether the four breast cancer-related SNPs in the FGFR2 gene (rs11200014, rs2981579, rs1219648, and rs2420946) [24] and the three common variants (tag-SNPs) in the FGFR4 gene (rs1966265, rs376618, and rs351855) are associated with the risk of three skin cancer types including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC).
###end p 14
###begin title 15
Methods
###end title 15
###begin p 16
###xml 144 146 144 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 42 47 <span type="species:ncbi:9606">women</span>
###xml 384 396 <span type="species:ncbi:9606">participants</span>
###xml 679 684 <span type="species:ncbi:9606">women</span>
###xml 936 948 <span type="species:ncbi:9606">participants</span>
###xml 1023 1028 <span type="species:ncbi:9606">Human</span>
###xml 1057 1062 <span type="species:ncbi:9606">Women</span>
Eligible cases in this study consisted of women with incident skin cancer from the subcohort of the NHS who gave a blood specimen in 1989-1990 (n = 32,826), including SCC and BCC cases with a diagnosis any time after blood collection up to June 1, 1998 and melanoma cases up to June 1, 2000 with no previously diagnosed skin cancer. A common control series was randomly selected from participants who gave a blood sample and were free of diagnosed skin cancer up to and including the questionnaire cycle during which the case was diagnosed. One or two controls were matched to each case by year of birth (+/- 1 year). All subjects were drawn from the U.S. non-Hispanic Caucasian women in this study. The nested case-control study consisted of 218 incident melanoma cases, 285 incident SCC cases, a sample of 300 BCC cases from the large number of incident cases, and 870 age-matched controls. The informed consent was obtained from the participants in this study. The study protocol was approved by the Committee on Use of Human Subjects of the Brigham and Women's Hospital, Boston, MA.
###end p 16
###begin p 17
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1113 1115 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 955 960 <span type="species:ncbi:9606">child</span>
###xml 1071 1076 <span type="species:ncbi:9606">women</span>
We obtained information regarding skin cancer risk factors from the prospective biennial questionnaires and a retrospective supplementary questionnaire. Information on natural hair color at age 20 and childhood and adolescent tanning tendency were collected in the 1982 prospective questionnaire. Ethnic group was ascertained in the 1992 questionnaire. In the skin cancer nested case-control study, natural skin color and other sun exposure-related information were collected by the retrospective supplementary questionnaire in 2002. The response rates of cases and controls were 92% and 89%, respectively. A cumulative lifetime sun exposure while wearing a bathing suit for each individual was developed by combining the UV database and the information obtained from the supplementary questionnaires. We constructed a multivariate confounder score to create a constitutional susceptibility score [37], summarizing natural skin color, natural hair color, child or adolescent tendency to burn, and the number of palpably raised moles on arms. We used this score to define women with constitutional susceptibility [38]. In addition, the 11 states of residence of cohort members at baseline were grouped into three regions: Northeast (Connecticut, Massachusetts, Maryland, New Jersey, New York, and Pennsylvania), Northcentral (Michigan and Ohio), and West and South (California, Texas, and Florida).
###end p 17
###begin p 18
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 81 82 81 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 320 326 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 800 801 800 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 851 853 851 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 933 935 933 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
Information on the seven SNPs in the FGFR2 and FGFR4 genes is presented in Table 1. Four SNPs in intron 2 of the FGFR2 gene (rs11200014, rs2981579, rs1219648, and rs2420946) genotyped in this study were breast cancer-related SNPs identified by a recent genome-wide association study conducted by our group [24]. For the FGFR4 gene, based on the HapMap phase II SNP genotype data, we chose three tag-SNPs (rs1966265, rs376618, and rs351855) as surrogates for untyped polymorphisms in the FGFR4 gene using the HapMap Project 90 (30 trios) Caucasian samples from a US Utah population with Northern and Western European ancestry collected in 1980 by the Centre d'Etude du Polymorphisme Humain (CEPH) [39]. Briefly, the tag-SNPs (minor allele frequency > 0.05) were selected using the Tagger program of (r2>0.8), which combines the simplicity of pairwise r2 methods [40] with the potential efficiency of multimarker haplotype approaches [41].
###end p 18
###begin p 19
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
Seven SNPs in the FGFR2 and FGFR4 genes
###end p 19
###begin p 20
###xml 79 81 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r2 = 0.8).
###end p 20
###begin p 21
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a Minor allele frequency (MAF) was calculated among controls in this study.
###end p 21
###begin p 22
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
b MAF was based on the HapMap CEU (Utah residents with ancestry from northern and western Europe) samples.
###end p 22
###begin p 23
###xml 62 65 62 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 186 190 184 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 246 250 242 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 359 365 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 377 379 371 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
We genotyped these seven SNPs by the 5' nuclease assay (TaqMan(R)) in 384-well format, using the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). TaqMan(R) primers and probes were designed with the Primer Express(R) Oligo Design software v2.0 (ABI PRISM). Due to assay failure, we genotyped rs12519145 as a surrogate for the FGFR4 rs1966265 (r2 = 0.8). Laboratory personnel were blinded to case-control status, and 10% blinded quality control samples (duplicate samples) were inserted to validate genotyping procedures; concordance for the blinded quality control samples was 100%. Primers, probes, and conditions for genotyping assays are available upon request.
###end p 23
###begin p 24
###xml 15 17 13 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 388 389 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 513 519 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 534 540 532 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 856 858 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
We used the chi2 test to assess whether the genotypes for all seven SNPs were in Hardy-Weinberg equilibrium among the controls. We compared each type of skin cancer with the common control series to increase the statistical power. We evaluated the association between each genotype and skin cancer risk using unconditional logistic regression. An additive model was used to calculate the p-value on skin cancer risk according to an ordinal coding for genotype (0, 1 or 2 copies of SNP minor allele). For the four FGFR2 SNPs and three FGFR4 SNPs, haplotype frequencies and expected haplotype counts for each individual were estimated using a simple expectation-maximization algorithm, as implemented in SAS PROC HAPLOTYPE. The analyses of the associations between haplotypes and skin cancer risk were performed using the expectation-substitution technique [42]. All statistical analyses were two-sided and carried out using SAS V9.1 (SAS Institute, Cary, NC).
###end p 24
###begin p 25
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
The Quanto statistical software version 1.2.3 was used for power calculation [43]. We calculated the power to detect the specified ORs at various allele frequencies of variant allele in additive models. The calculations were based on a two-sided alpha of 0.05. For melanoma (SCC or BCC), we have 80% power to detect an OR of 1.80 (1.72 or 1.70), 1.48 (1.42 or 1.41), and 1.35 (1.32 or 1.31) if the minor allele frequency is 5%, 15%, and 40%, respectively.
###end p 25
###begin title 26
Results and discussion
###end title 26
###begin p 27
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
A detailed description of the characteristics of cases and controls in the skin cancer nested case-control study has been provided previously [44]. In brief, at the beginning of the follow-up of this nested case-control study, the nurses were between 43 and 68 years old (mean age, 58.7 years). The mean ages at diagnosis for incident melanoma, SCC, and BCC cases were 63.4, 64.7, and 64.0 years, respectively. A family history of skin cancer was a risk factor for all three types of skin cancer. Skin cancer cases had lighter pigmentation (skin color and hair color), more moles on the arms, higher cumulative sun exposure while wearing a bathing suit, and more lifetime severe sunburns that blistered than controls.
###end p 27
###begin p 28
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 642 648 642 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 652 658 652 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 714 715 714 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 862 863 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The genotype distributions of the seven SNPs evaluated in this study were in Hardy-Weinberg equilibrium among controls. The minor allele frequencies of these seven SNPs among controls in this study were similar to those from HapMap CEU data. We evaluated the main effect of each polymorphism across three types of skin cancer (Table 2) and observed no significant associations between these seven SNPs and skin cancer risk. The multivariate analyses controlling for age and skin cancer risk factors showed results similar to the age-adjusted analyses (Additional file 1). Furthermore, we performed a global test to evaluate the difference in FGFR2 and FGFR4 haplotype frequencies between cases and controls (Table 3) and found no significant associations with skin cancer risk, which was consistent with the results of the single SNP analyses presented in Table 2.
###end p 28
###begin p 29
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
Associations between the seven SNPs in the FGFR2 and FGFR4 genes and skin cancer risk
###end p 29
###begin p 30
*Unconditional logistic regression adjusted for age.
###end p 30
###begin p 31
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
**The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r2 = 0.8).
###end p 31
###begin p 32
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
Haplotypes for the SNPs in the FGFR2 and FGFR4 genes and skin cancer risk
###end p 32
###begin p 33
0, common allele; 1, rare allele.
###end p 33
###begin p 34
Logistic regression adjusted for age.
###end p 34
###begin p 35
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
p-values for global tests are >0.05.
###end p 35
###begin p 36
###xml 79 81 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r2 = 0.8).
###end p 36
###begin p 37
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF2 </italic>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 549 555 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 727 733 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 820 826 820 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1311 1313 1311 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1316 1322 1316 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 1476 1478 1476 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1494 1503 1494 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 1507 1515 1507 1515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 1552 1558 1552 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 1600 1602 1600 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1715 1721 1715 1721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
The potential contribution of the FGF/FGFR family to the development of skin cancer has been suggested. For example, the basic FGF (bFGF) alternatively named FGF2 binds to distinct splice variants of the four FGFRs and acts as a potent activator in the proliferation and differentiation of melanocytes [45]. It has been noted that the combination of bFGF with ultraviolet (UV) light, the main risk factor for skin cancer, may lead to cutaneous melanoma induction [46]. In this study, we assessed the associations between the genetic variants in the FGFR2 and FGFR4 genes and the three types of skin cancer simultaneously with a modest sample size in each cancer type. Only one study has attempted to assess the relation of the FGFR4 Gly388Arg with the progression of melanoma in melanoma patients, and observed that the FGFR4 Arg388 allele was associated with tumor thickness and nodular malignant melanoma [26]. We did not observe a significant association of this allele with skin cancer risk. It seems that this SNP acts as a potential marker for the progression of skin cancer rather than susceptibility to skin cancer. Spinola et al. reported similar results for lung adenocarcinoma, i.e., that this allele revealed association with progression of cancer but a lack of association with the risk of cancer [33]. FGFR2 possesses the largest genomic structure among the FGFR family, with at least 22 exons and 21 introns and has been implicated in distinct types of cancer [47]. Also, recent in vitro and in vivo studies showed that loss-of-function FGFR2 mutations occur in a subset of melanomas [48]. It would be important to comprehensively examine the association of the common genetic variants in the entire FGFR2 gene region with skin cancer risk.
###end p 37
###begin title 38
Conclusion
###end title 38
###begin p 39
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 157 162 <span type="species:ncbi:9606">women</span>
In conclusion, we did not detect any contribution of genetic variants in the FGFR2 or FGFR4 genes to inherited predisposition to skin cancer among Caucasian women.
###end p 39
###begin title 40
List of Abbreviations
###end title 40
###begin p 41
###xml 0 4 0 4 <bold xmlns:xlink="http://www.w3.org/1999/xlink">FGFR</bold>
###xml 41 44 41 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BCC</bold>
###xml 68 71 68 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SCC</bold>
###xml 98 100 98 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OR</bold>
###xml 114 116 114 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CI</bold>
###xml 139 141 139 141 <bold xmlns:xlink="http://www.w3.org/1999/xlink">UV</bold>
FGFR: Fibroblast Growth Factor Receptor; BCC: Basal Cell Carcinoma; SCC: Squamous Cell Carcinoma; OR: Odds Ratio; CI: Confidence Interval; UV: Ultraviolet.
###end p 41
###begin title 42
Competing interests
###end title 42
###begin p 43
The authors declare that they have no competing interests.
###end p 43
###begin title 44
Authors' contributions
###end title 44
###begin p 45
All authors have contributed to designing the study and analyzing and interpreting the data, as well as to the writing of the manuscript. All authors have read and approved this manuscript.
###end p 45
###begin title 46
Pre-publication history
###end title 46
###begin p 47
The pre-publication history for this paper can be accessed here:
###end p 47
###begin p 48

###end p 48
###begin title 49
Supplementary Material
###end title 49
###begin title 50
Additional File 1
###end title 50
###begin p 51
###xml 67 73 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR2 </italic>
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGFR4 </italic>
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Supplementary Table S1. Associations between the seven SNPs in the <italic>FGFR2 </italic>and <italic>FGFR4 </italic>genes and skin cancer risk</bold>
Supplementary Table S1. Associations between the seven SNPs in the FGFR2 and FGFR4 genes and skin cancer risk. The data provided represent the results of the associations between seven SNPs in the FGFR2 and FGFR4 genes and skin cancer risk.
###end p 51
###begin p 52
Click here for file
###end p 52
###begin title 53
Acknowledgements
###end title 53
###begin p 54
###xml 235 247 <span type="species:ncbi:9606">participants</span>
We thank Dr. Hardeep Ranu and Ms. Pati Soule of the Dana-Farber/Harvard Cancer Center High-Throughput Polymorphism Detection Core for their laboratory assistance, and Ms. Carolyn Guo for her programming support. We are indebted to the participants in the Nurses' Health Study for their dedication and commitment. This work was supported by National Institutes of Health research grants CA122838 and CA132175.
###end p 54
###begin article-title 55
Evolution of the Fgf and Fgfr gene families
###end article-title 55
###begin article-title 56
Fibroblast growth factors
###end article-title 56
###begin article-title 57
Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1
###end article-title 57
###begin article-title 58
Receptor specificity of the fibroblast growth factor family
###end article-title 58
###begin article-title 59
Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2)
###end article-title 59
###begin article-title 60
###xml 137 142 <span type="species:ncbi:10090">mouse</span>
Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse
###end article-title 60
###begin article-title 61
###xml 143 148 <span type="species:ncbi:10090">mouse</span>
FGFR-4, a new member of the fibroblast growth factor receptor family, expressed in the definitive endoderm and skeletal muscle lineages of the mouse
###end article-title 61
###begin article-title 62
Structural and functional diversity in the FGF receptor multigene family
###end article-title 62
###begin article-title 63
Signal transduction by fibroblast growth factor receptors
###end article-title 63
###begin article-title 64
###xml 56 61 <span type="species:ncbi:9606">women</span>
Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis
###end article-title 64
###begin article-title 65
Cellular signaling by fibroblast growth factor receptors
###end article-title 65
###begin article-title 66
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 90 95 <span type="species:ncbi:9606">human</span>
Keratinocyte growth factor in the promotion of human chorionic gonadotropin production in human choriocarcinoma cells
###end article-title 66
###begin article-title 67
Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development, and differentiation. Normalization of the nu/nu follicular differentiation defect and amelioration of chemotherapy-induced alopecia
###end article-title 67
###begin article-title 68
###xml 83 98 <span type="species:ncbi:10090">transgenic mice</span>
Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation
###end article-title 68
###begin article-title 69
Keratinocyte growth factor: a unique player in epithelial repair processes
###end article-title 69
###begin article-title 70
The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development
###end article-title 70
###begin article-title 71
Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer
###end article-title 71
###begin article-title 72
###xml 111 116 <span type="species:ncbi:9606">human</span>
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers
###end article-title 72
###begin article-title 73
Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression
###end article-title 73
###begin article-title 74
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes
###end article-title 74
###begin article-title 75
###xml 77 82 <span type="species:ncbi:9606">human</span>
Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer
###end article-title 75
###begin article-title 76
###xml 100 105 <span type="species:ncbi:9606">human</span>
Restoration of fibroblast growth factor receptor2 suppresses growth and tumorigenicity of malignant human prostate carcinoma PC-3 cells
###end article-title 76
###begin article-title 77
Genome-wide association study identifies novel breast cancer susceptibility loci
###end article-title 77
###begin article-title 78
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
###end article-title 78
###begin article-title 79
###xml 47 52 <span type="species:ncbi:9606">human</span>
Genomic structure and complete sequence of the human FGFR4 gene
###end article-title 79
###begin article-title 80
###xml 108 116 <span type="species:ncbi:9606">patients</span>
FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients
###end article-title 80
###begin article-title 81
###xml 31 36 <span type="species:ncbi:9606">human</span>
Amplification of fgfr4 gene in human breast and gynecological cancers
###end article-title 81
###begin article-title 82
###xml 87 92 <span type="species:ncbi:9606">human</span>
Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer
###end article-title 82
###begin article-title 83
Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer
###end article-title 83
###begin article-title 84
Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique
###end article-title 84
###begin article-title 85
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele
###end article-title 85
###begin article-title 86
Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis
###end article-title 86
###begin article-title 87
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients
###end article-title 87
###begin article-title 88
Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma
###end article-title 88
###begin article-title 89
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer
###end article-title 89
###begin article-title 90
The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression
###end article-title 90
###begin article-title 91
Stratification by a multivariate confounder score
###end article-title 91
###begin article-title 92
Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study
###end article-title 92
###begin article-title 93
###xml 84 89 <span type="species:ncbi:9606">human</span>
Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome
###end article-title 93
###begin article-title 94
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium
###end article-title 94
###begin article-title 95
Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals
###end article-title 95
###begin article-title 96
Accounting for haplotype uncertainty in matched association studies: a comparison of simple and flexible techniques
###end article-title 96
###begin article-title 97
QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies
###end article-title 97
###begin article-title 98
Genetic variation in XPD, sun exposure, and risk of skin cancer
###end article-title 98
###begin article-title 99
Biological roles of fibroblast growth factor-2
###end article-title 99
###begin article-title 100
###xml 74 79 <span type="species:ncbi:9606">human</span>
Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin
###end article-title 100
###begin article-title 101
Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and variations
###end article-title 101
###begin article-title 102
Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma
###end article-title 102

